GeneDx Holdings (WGS) reported adjusted net income Tuesday of $16.8 million compared with an adjusted net loss of $17.8 million a year earlier.
Two analysts surveyed by FactSet expected $1.6 million.
Revenue for the quarter ended Dec. 31 was $95.6 million, up from $58.1 million a year earlier.
Analysts surveyed by FactSet expected $82.2 million.
For the full year, GeneDx expects revenue between $350 million and $360 million, with growth in exome/genome volume and revenue of at least 30%.
Analysts surveyed by FactSet expect $338.8 million.
The company's shares were up more than 25% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。